Capital One Financial Corp. vs Sana Biotechnology Inc — how do they compare? Capital One Financial Corp. trades at $222.01 (market cap $134.45B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Capital One Financial Corp. is far larger — about 119× Sana Biotechnology Inc's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| COF | SANA | |
|---|---|---|
Market Cap | $134.45B | $1.13B |
Sector | Financials | Health |
52-Week High | $257.94 | $5.92 |
52-Week Low | $176.10 | $2.68 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $1.05B |
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $223.09, up 1.88% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.07 and P/B of 1.18, while Q2 2026 earnings beat expectations. Recent news highlights the Discover integration progress and a 20-year arena naming rights extension, reinforcing brand commitment.
The outlook is positive with a consensus price target of $251.60, implying 13% upside, supported by 63% analyst buy ratings. Key risks include integration execution of Discover, credit loss provisions, and macroeconomic sensitivity. Revenue growth to $62.0B in 2026 projects a net income margin rebound to 16.96%, offering a compelling value proposition if synergies materialize.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Trailing returns across standard periods
Latest headlines on both assets
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →